PDCD1 and neoplasm: Indeed, studies have demonstrated that after administration, anti-PD-1 mAb binds to tumor-infiltrating T cells at an early stage but is subsequently captured by TAMs due to the presence of Fcγ receptors, which ultimately leads to drug failure (53, 54).